Iron depletion enhances the effect of sorafenib in hepatocarcinoma

References

• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-17; PMID:14667750; http://dx.doi.org/10.1016/S0140-6736(03)14964-1
   PubMed Web of Science ®Google Scholar
• Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002; 963:13-20; PMID:12095924; http://dx.doi.org/10.1111/j.1749-6632.2002.tb04090.x
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-109; PMID:15466206; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-8; PMID:17178882; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377
   PubMed Web of Science ®Google Scholar
• Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009; 100:9-16; PMID:19018762; http://dx.doi.org/10.1111/j.1349-7006.2008.01001.x
   PubMed Web of Science ®Google Scholar
• Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. British J Cancer 1989; 60:708-11; PMID:2803947; http://dx.doi.org/10.1038/bjc.1989.344
   PubMed Web of Science ®Google Scholar
• Jiang L, Akatsuka S, Nagai H, Chew SH, Ohara H, Okazaki Y, Yamashita Y, Yoshikawa Y, Yasui H, Ikuta K, et al. Iron overload signature in chrysotile-induced malignant mesothelioma. J Pathol 2012; 228:366-77; PMID:22864872; http://dx.doi.org/10.1002/path.4075
   PubMed Web of Science ®Google Scholar
• Hann HW, Stahlhut MW, Blumberg BS. Iron nutrition and tumor growth: decreased tumor growth in iron-deficient mice. Cancer Res 1988; 48:4168-70; PMID:3390810
   PubMed Web of Science ®Google Scholar
• Yu Y, Suryo Rahmanto Y, Richardson DR. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. British J Pharmacol 2012; 165:148-66; PMID:21658021; http://dx.doi.org/10.1111/j.1476-5381.2011.01526.x
   PubMed Web of Science ®Google Scholar
• Ohara T, Noma K, Urano S, Watanabe S, Nishitani S, Tomono Y, Kimura F, Kagawa S, Shirakawa Y, Fujiwara T. A novel synergistic effect of iron depletion on antiangiogenic cancer therapy. Int J Cancer J Int du Cancer 2013; 132:2705-13; PMID:23161652; http://dx.doi.org/10.1002/ijc.27943
   PubMed Web of Science ®Google Scholar
• Kew MC. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer 2014; 3:31-40; PMID:24804175; http://dx.doi.org/10.1159/000343856
   PubMed Web of Science ®Google Scholar
• Tirnitz-Parker JE, Glanfield A, Olynyk JK, Ramm GA. Iron and hepatic carcinogenesis. Crit Rev Oncog 2013; 18:391-407; PMID:23879586; http://dx.doi.org/10.1615/CritRevOncog.2013007759
   PubMedGoogle Scholar
• Horl WH, Schmidt A. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C. Nephrol Dial Transplant 2014; 29:1141-4; PMID:24286977; http://dx.doi.org/10.1093/ndt/gft467
   PubMed Web of Science ®Google Scholar
• Beckman LE, Hagerstrand I, Stenling R, Van Landeghem GF, Beckman L. Interaction between haemochromatosis and transferrin receptor genes in hepatocellular carcinoma. Oncology 2000; 59:317-22; PMID:11096344; http://dx.doi.org/10.1159/000012189
   PubMed Web of Science ®Google Scholar
• Chen J, Chloupkova M. Abnormal iron uptake and liver cancer. Cancer Biol Ther 2009; 8:1699-708; PMID:19571663; http://dx.doi.org/10.4161/cbt.8.18.9146
   PubMed Web of Science ®Google Scholar
• Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, Yu HS. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 2009; 135:1413-20; PMID:19387685; http://dx.doi.org/10.1007/s00432-009-0585-5
   PubMed Web of Science ®Google Scholar
• Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, Kawano Y, Takahashi S, Takahashi M, Sato Y, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42:830-6; PMID:17940836; http://dx.doi.org/10.1007/s00535-007-2095-z
   PubMed Web of Science ®Google Scholar
• Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, Loreal O, Brissot P, Lescoat G. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Biometals 2010; 23:231-45; PMID:19997770; http://dx.doi.org/10.1007/s10534-009-9281-9
   PubMed Web of Science ®Google Scholar
• Ba Q, Hao M, Huang H, Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, et al. Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies. Clin Cancer Res 2011; 17:7625-33; PMID:22052937; http://dx.doi.org/10.1158/1078-0432.CCR-10-3099
   PubMed Web of Science ®Google Scholar
• Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol 2013; 83:179-90; PMID:23074173; http://dx.doi.org/10.1124/mol.112.081893
   PubMed Web of Science ®Google Scholar
• Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 2008; 14:5099-107; PMID:18698027; http://dx.doi.org/10.1158/1078-0432.CCR-08-0255
   PubMed Web of Science ®Google Scholar
• Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55:5187-90; PMID:7585571
   PubMed Web of Science ®Google Scholar
• Wettersten HI, Hee Hwang S, Li C, Shiu EY, Wecksler AT, Hammock BD, Weiss RH. A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther 2013; 14:278-85; PMID:23298903; http://dx.doi.org/10.4161/cbt.23374
   PubMed Web of Science ®Google Scholar
• Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, Chieco P, Gramantieri L, Bolondi L. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget 2013; 4:1618-31; PMID:24113128; http://dx.doi.org/10.18632/oncotarget.1221
   PubMed Web of Science ®Google Scholar
• Inoue H, Hwang SH, Wecksler AT, Hammock BD, Weiss RH. Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy. Cancer Biol Ther 2011; 12:827-36; PMID:21878748; http://dx.doi.org/10.4161/cbt.12.9.17680
   PubMed Web of Science ®Google Scholar
• Fu D, Richardson DR. Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion. Blood 2007; 110:752-61; PMID:17429006; http://dx.doi.org/10.1182/blood-2007-03-076737
   PubMed Web of Science ®Google Scholar
• Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochimica et biophysica acta 2013; 1836:245-54; PMID:23891969; http://dx.doi.org/10.1016/j.bbcan.2013.07.002
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investigational new drugs 1999; 17:343-59; PMID:10759402; http://dx.doi.org/10.1023/A:1006326203858
   PubMed Web of Science ®Google Scholar
• Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 2015; 15:451-2; PMID:26422835; http://dx.doi.org/10.1038/nrc3972
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Jiang P, Yang M, Xu M, Yamauchi K, Tsuchiya H, Tomita K, Wahl GM, Moossa AR, Hoffman RM. Cellular dynamics visualized in live cells in vitro and in vivo by differential dual-color nuclear-cytoplasmic fluorescent-protein expression. Cancer Res 2004; 64:4251-6; PMID:15205338; http://dx.doi.org/10.1158/0008-5472.CAN-04-0643
   PubMed Web of Science ®Google Scholar
• Hoffman RM, Yang M. Subcellular imaging in the live mouse. Nature protocols 2006; 1:775-82; PMID:17406307; http://dx.doi.org/10.1038/nprot.2006.109
   PubMed Web of Science ®Google Scholar
• Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005; 5:796-806; PMID:16195751; http://dx.doi.org/10.1038/nrc1717
   PubMed Web of Science ®Google Scholar
• Yang M, Jiang P, Hoffman RM. Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm. Anticancer Res 2015; 35:2539-43; PMID:25964527
   PubMed Web of Science ®Google Scholar
• Uchida T, Akitsuki T, Kimura H, Tanaka T, Matsuda S, Kariyone S. Relationship among plasma iron, plasma iron turnover, and reticuloendothelial iron release. Blood 1983; 61:799-802; PMID:6403079
   PubMed Web of Science ®Google Scholar